Switch to:
More From Other Websites
What Do Analysts Say about Regeneron’s Upside Potential? Sep 30 2016
BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US :... Sep 30 2016
Sarepta's Costly Muscular Dystrophy Drug Flirts With Big Pharma M&A Sep 28 2016
What’s the Upward Return Potential for BioMarin? Sep 28 2016
What’s the Word on Street for Vertex? Sep 28 2016
Sarepta: 'Yes, We're Aware Our Price Target is $50 Higher Than the Current Price' Sep 28 2016
A Look at BioMarin’s Early Stage Pipeline Sep 28 2016
How Promising is BioMarin’s Late-Stage Pipeline? Sep 27 2016
BioMarin to Cross $1 Billion Revenue in 2016 Sep 27 2016
What Are BioMarin’s Valuation Drivers? Sep 27 2016
BioMarin Takes Aim at Rival Sarepta (BMRN, SRPT) Sep 26 2016
Blue Jay Capital Betting On Big Returns From These Healthcare Stocks Sep 22 2016
Sarepta (SRPT) Stock Lower, BioMarin to Appeal Patent Ruling Sep 21 2016
Sarepta Therapeutics: BioMarin Still Wants a Piece of the Action Sep 21 2016
Patent Trial And Appeal Board Hands Sarepta Another Big Win Sep 21 2016
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases... Sep 21 2016
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases... Sep 21 2016
[$$] Sarepta Soars 100% in a Week Yet Remains a Buy Sep 20 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK